IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype

Human Pathology

Volumn 40, Issue 11, 2009, Pages 1528-1533

  Walter, Otto ^a   Prasad, Manju ^a   Lu, Shaolei ^b   Quinlan, Robert M ^a   Edmiston, Kathryn L ^a   Khan, Ashraf ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Basal like carcinoma; Breast carcinoma; Immunohistochemistry; IMP3; Invasive ductal carcinoma

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FORMALDEHYDE; IMP3 PROTEIN; ONCOFETAL ANTIGEN; PARAFFIN; PROGESTERONE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER INVASION; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL STRUCTURE; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE DUCTAL CARCINOMA; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; NECROSIS; PHENOTYPE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM PROTEINS; PHENOTYPE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349858255     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.05.005     Document Type: Article

References (29)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Fitzgibbons P.L., Page D.L., Weaver D., et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124 (2000) 966-978
3. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
4. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 (2001) 10869-10874
5. Carey L.A., Dees E.C., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13 (2007) 2329-2334
6. Nielsen J., Christiansen J., Lykke-Andersen J., Johnsen A.H., Wewer U.M., and Nielsen F.C. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19 (1999) 1262-1270
7. Mueller-Pillasch F., Pohl B., Wilda M., et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 88 (1999) 95-99
8. Mueller-Pillasch F., Lacher U., Wallrapp C., et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 14 (1997) 2729-2733
9. Yantiss R.K., Woda B.A., Fanger G.R., et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 29 (2005) 188-195
10. Simon R., Bourne P.A., Yang Q., et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol 38 (2007) 1178-1183
11. Wang T., Fan L., Watanabe Y., et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 88 (2003) 887-894
12. Li C., Rock K.L., Woda B.A., Jiang Z., Fraire A.E., and Dresser K. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol 20 (2007) 242-247
13. Jiang Z., Chu P.G., Woda B.A., et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 7 (2006) 556-564
14. Sitnikova L., Mendese G., Liu Q., et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 14 (2008) 1701-1706
15. Zheng W., Yi X., Fadare O., et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 32 (2008) 304-315
16. Liao B., Hu Y., Herrick D.J., and Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 280 (2005) 18517-18524
17. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 5 (2000) 95-105
18. Yee D., and Lee A.V. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 5 (2000) 107-115
19. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
20. Greene F.L., and American Joint Committee on Cancer. American Cancer Society. AJCC cancer staging manual (2002), Springer-Verlag, New York
21. Livasy C.A., Karaca G., Nanda R., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19 (2006) 264-271
22. Rakha E.A., El-Sayed M.E., Green A.R., Paish E.C., Lee A.H., and Ellis I.O. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 50 (2007) 434-438
23. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
24. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
25. Berry D.A., Cirrincione C., Henderson I.C., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295 (2006) 1658-1667
26. Vikesaa J., Hansen T.V., Jonson L., et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 25 (2006) 1456-1468
27. Yaniv K., Fainsod A., Kalcheim C., and Yisraeli J.K. The RNA-binding protein Vg1 RBP is required for cell migration during early neural development. Development 130 (2003) 5649-5661
28. Jiang Z., Lohse C.M., Chu P.G., et al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 112 (2008) 2676-2682
29. Yaniv K., and Yisraeli J.K. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene 287 (2002) 49-54